Molecular neuroscience

Insomnia Data 2020: US Leads in Global Insomnia Clinical Trials, Germany Leads Major European Markets and Japan Has Top Spot in Asia

Retrieved on: 
Thursday, May 21, 2020
Branches of biology, G protein-coupled receptors, Protein families, Molecular neuroscience, Orexin receptor, Orexin, RTT, gamma-Aminobutyric acid, GABAA receptor, Insomnia, Hypocretin (orexin) receptor 1, Nemorexant

It is estimated that Asia had the largest number of prevalent cases in 2017 (675.7 million cases).

Key Points: 
  • It is estimated that Asia had the largest number of prevalent cases in 2017 (675.7 million cases).
  • The approved drugs in the insomnia space target GABA-A receptor, hypocretin/orexin receptor, chloride channel 2, chloride, melatonin receptor, histamine H1 receptor, and potassium channels.
  • Germany leads the major European markets, while Japan has the top spot in Asia.
  • Takeda leads the industry sponsors with the highest overall number of clinical trials for insomnia, followed by Merck & Co.

Protecting a Most Precious Asset: GABA Proved to Fortify Cognitive Health in Human Trials

Retrieved on: 
Tuesday, March 31, 2020
Alternative medicine, General Health, Fitness & Nutrition, Health, Branches of biology, Neuroscience, Neurochemistry, Neurotransmitters, Amino acids, Molecular neuroscience, Biology of obsessive–compulsive disorder, gamma-Aminobutyric acid, Aminobutyric acid, gamma-Amino-beta-hydroxybutyric acid, GABBR1

They want to have agency over the state of their mental health as they age, as they do their physical health.

Key Points: 
  • They want to have agency over the state of their mental health as they age, as they do their physical health.
  • The benefits of the naturally-occurring amino acid neurotransmitter GABA [-Aminobutyric acid], found across a range of healthful foods, have never really been in doubt.
  • It has long been known that a decreased systemic level of GABA is associated with the presence of Parkinsons disease, epilepsy, Huntingtons chorea, Alzheimers disease, and schizophrenia.
  • The current studies published by Pharma Foods International offer the promise that a naturally-occurring, naturally derived supplement, GABA, may lead the way.

2020 Market Spotlight: Insomnia -- Eisai Buys Out Global Rights to Lemborexant - ResearchAndMarkets.com

Retrieved on: 
Monday, March 30, 2020
Health, Pharmaceutical, Branches of biology, Chemical compounds, Psychoactive drugs, G protein-coupled receptors, Protein families, Hypnotics, Molecular neuroscience, RTT, Orexin receptor, Orexin, Insomnia, gamma-Aminobutyric acid

It is estimated that Asia had the largest number of prevalent cases in 2017 (675.7 million cases).

Key Points: 
  • It is estimated that Asia had the largest number of prevalent cases in 2017 (675.7 million cases).
  • The approved drugs in the insomnia space target GABA-A receptor, hypocretin/orexin receptor, chloride channel 2, chloride, melatonin receptor, histamine H1 receptor, and potassium channels.
  • The largest proportion of industry-sponsored drugs in active clinical development for insomnia are in Phase III, with only one drug in the NDA/BLA phase.
  • Takeda leads the industry sponsors with the highest overall number of clinical trials for insomnia, followed by Merck & Co.

Isotopia Molecular Imaging and Eckert & Ziegler to Start Partnership for Prostate Cancer Imaging

Retrieved on: 
Thursday, February 13, 2020
Branches of biology, Medicine, Medical physics, Glutamate carboxypeptidase II, Molecular neuroscience, Neurotransmitters, Peptidase, Medicinal radiochemistry, Molecular imaging, Prostate cancer, Positron emission tomography

PETACH TIKVA, Israel, Feb. 13, 2020 /PRNewswire/ -- Isotopia Molecular Imaging is pleased to announce that is has entered into a development partnership with Eckert & Ziegler for the development of its PSMA-11-Kit for prostate cancer imaging.

Key Points: 
  • PETACH TIKVA, Israel, Feb. 13, 2020 /PRNewswire/ -- Isotopia Molecular Imaging is pleased to announce that is has entered into a development partnership with Eckert & Ziegler for the development of its PSMA-11-Kit for prostate cancer imaging.
  • Under the terms of the agreement, E&Z and Isotopia will partner to finalize the development of Isotopia's68Ga-HBED-CC-PSMA (68Ga-PSMA-11) kit (Kit), a technology for imaging and staging of prostate cancer.
  • Isotopia's head of Business development, Keren Moshkoviz stated, "We are excited in taking another significant step towards making prostate cancer imaging more accessible.
  • PSMA-11 radiolabeled with68Ga (gallium) is a convenient and clinically efficient approach to imaging prostate cancer with Positron Emission Tomography (PET).

Prothena Reports Fourth Quarter and Full Year 2019 Financial Results, and Provides Financial Guidance and R&D Update

Retrieved on: 
Wednesday, February 12, 2020
Alzheimer's disease, Molecular neuroscience, Asset, Cash, Cash and cash equivalents, Amyloid beta, Biology, Life sciences, Biotechnology

In addition, the Company provided 2020 financial guidance and an update on its R&D programs.

Key Points: 
  • In addition, the Company provided 2020 financial guidance and an update on its R&D programs.
  • In 2019, we continued to advance our pipeline of novel investigational therapeutics towards key milestones, said Gene Kinney, Ph.D., President and Chief Executive Officer of Prothena.
  • Initiated cell line development of a lead candidate in the proprietary preclinical A (Amyloid beta) program in the fourth quarter of 2019.
  • As of December31, 2019, Prothena had $378.4 million in cash, cash equivalents and restricted cash and no debt.

Sosei Heptares: Significant Progress by Orexia and Inexia With Orexin Agonist Program Triggers Next Tranche of Funding From Medicxi

Retrieved on: 
Tuesday, January 14, 2020
Branches of biology, Biology, G protein-coupled receptors, Molecular neuroscience, Neuropeptides, Protein families, Orexin, Hypocretin (orexin) receptor 2, Narcolepsy, Hypocretin (orexin) receptor 1

Mario Alberto Accardi Ph.D., CEO of Orexia and Inexia, commented:"We have assembled a unique orexin modulator drug discovery and design engine at Orexia and Inexia, based around Sosei Heptares' SBDD and GPCR technology.

Key Points: 
  • Mario Alberto Accardi Ph.D., CEO of Orexia and Inexia, commented:"We have assembled a unique orexin modulator drug discovery and design engine at Orexia and Inexia, based around Sosei Heptares' SBDD and GPCR technology.
  • This significant and exciting progress has triggered the investment of further committed funds from Medicxi that will be deployed to rapidly advance these highly promising molecules towards the clinic."
  • Dr. Malcolm Weir, Executive Vice President, Research & Early Development at Sosei Heptares, added: "We are very pleased with the progress being made in the orexin agonist program in collaboration with Orexia and Inexia and with support and funding from Medicxi.
  • Orexia and Inexia are focused on developing Orexin OX1 and OX2 positive modulators and products derived therefrom, including dual OX1/OX2 agonists, targeting neurological diseases including narcolepsy.

Sosei Heptares: Significant Progress by Orexia and Inexia With Orexin Agonist Program Triggers Next Tranche of Funding From Medicxi

Retrieved on: 
Tuesday, January 14, 2020
Branches of biology, Biology, G protein-coupled receptors, Molecular neuroscience, Neuropeptides, Protein families, Orexin, Hypocretin (orexin) receptor 2, Narcolepsy, Hypocretin (orexin) receptor 1

Mario Alberto Accardi Ph.D., CEO of Orexia and Inexia, commented:"We have assembled a unique orexin modulator drug discovery and design engine at Orexia and Inexia, based around Sosei Heptares' SBDD and GPCR technology.

Key Points: 
  • Mario Alberto Accardi Ph.D., CEO of Orexia and Inexia, commented:"We have assembled a unique orexin modulator drug discovery and design engine at Orexia and Inexia, based around Sosei Heptares' SBDD and GPCR technology.
  • This significant and exciting progress has triggered the investment of further committed funds from Medicxi that will be deployed to rapidly advance these highly promising molecules towards the clinic."
  • Dr. Malcolm Weir, Executive Vice President, Research & Early Development at Sosei Heptares, added: "We are very pleased with the progress being made in the orexin agonist program in collaboration with Orexia and Inexia and with support and funding from Medicxi.
  • Orexia and Inexia are focused on developing Orexin OX1 and OX2 positive modulators and products derived therefrom, including dual OX1/OX2 agonists, targeting neurological diseases including narcolepsy.

Alzheon Publication Defines New Path for 2nd Generation Anti-Amyloid Drugs for Alzheimer’s Disease, Supporting Launch of Phase 3 Study with ALZ-801 Oral Tablet

Retrieved on: 
Wednesday, November 6, 2019
Biotechnology, Pharmaceutical, Health, Clinical trials, Branches of biology, Biology, Alzheimer's disease, Neuroscience, Alzheon, Molecular neuroscience, Histopathology, Amyloid beta, Amyloid, ALZ-801, Alzheon

This improved pharmacological profile will enable anti-amyloid drugs to achieve robust and meaningful clinical efficacy, and to realize the full potential of this most promising class of Alzheimers medicines.

Key Points: 
  • This improved pharmacological profile will enable anti-amyloid drugs to achieve robust and meaningful clinical efficacy, and to realize the full potential of this most promising class of Alzheimers medicines.
  • These insights have also guided Alzheon strategy in developing ALZ-801, which is the only remaining Phase 3 candidate with the attributes required for the next generation of anti-amyloid therapies.
  • Furthermore, the lack of selectivity leads to clearance of amyloid plaques that may contribute to vascular injury resulting in brain edema and microhemorrhages.
  • Our lead Alzheimers clinical candidate, ALZ-801 , is a Phase 3-ready, first-in-class, small molecule oral inhibitor of beta amyloid aggregation and neurotoxicity hallmarks of Alzheimers disease.

VistaGen Therapeutics Announces Last Patient Completes Dosing in the ELEVATE Phase 2 Clinical Study of AV-101 for Major Depressive Disorder

Retrieved on: 
Tuesday, October 8, 2019
Drugs, Branches of biology, Psychoactive drugs, NMDA receptor antagonists, Chloroarenes, Antidepressants, Nicotinic antagonists, Molecular neuroscience, NMDA receptor, 7-Chlorokynurenic acid, 4-Chlorokynurenine, Kynurenic acid

The Company remains on track to report top line results of the ELEVATE study before the end of 2019.

Key Points: 
  • The Company remains on track to report top line results of the ELEVATE study before the end of 2019.
  • The NMDA receptor is a pivotal receptor in the brain and abnormal NMDA function is associated with numerous CNS diseases and disorders.
  • AV-101 is an oral prodrug of 7-Cl-KYNA, a potent and selective full antagonist of the glycine coagonist site of the NMDA receptor.
  • The primary endpoint of the ELEVATE study is the change from baseline on the Montgomery-sberg Depression Rating Scale (MADRS-10) total score.

Further Data Review Shows Major Clinical Benefits From Veyonda®

Retrieved on: 
Monday, September 30, 2019
Branches of biology, Health sciences, Health, Prostate cancer, Glutamate carboxypeptidase II, Molecular neuroscience, Neurotransmitters, Peptidase, Management of prostate cancer, Therapy

The three endpoints used to measure anti-cancer effect all showed a benefit from combining Veyonda with 177Lu-PSMA therapy.

Key Points: 
  • The three endpoints used to measure anti-cancer effect all showed a benefit from combining Veyonda with 177Lu-PSMA therapy.
  • Adding Veyonda to 177Lu-PSMA therapy almost doubled the PSA response (69% with Veyonda vs 36% with 177Lu-PSMA alone).
  • In summary, combination therapy of Veyonda and 177Lu-PSMA therapy shows benefits to patients well above that with 177Lu-PSMA therapy alone and underscores the Companys confidence in Veyonda eventually becoming a standard drug in the management of prostate cancer.
  • Following safety data review of the first cohort (400 mg Veyonda), the dose for patients 9-16 was escalated to 800mg Veyonda for 10 days.